Nora Therapeutics, Inc.

MONTREAL, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today issued a letter to shareholders from Dr. Steve Slilaty, Chairman and CEO of the Company. Dear Fellow Sunshine Biopharma Shareholders, On behalf of Sunshine’s Board of Directors, our senior management team, and employees, we are delighted to have you as our shareholders and as valued stakeholders of our corporate family. I am writing this letter to provide you with some of the important developments that have occurred at Sunshine over this past year and some insights into what we see ahead. 2022 has been a transformative year for the Company despite some challenging headwinds with the economy and financial markets. On February 17, we completed an $8 million public offering and up-listed to NASDAQ. Shortly thereafter on March 14, we completed a private placement for total gross proceeds of another $8 million and on April 28 we closed a third offering for $19.5 million in gross proceeds. These offerings, together with additional funds of approximately $12 million received from the exercise of warrants included in the aforesaid offerings, enabled us to expand our proprietary drug development program and complete a key acquisition which set us on the path of becoming a fully-integrated biopharma company. In April, 2022, we announced our biopharma pipeline developments for mRNA molecules capable of destroying multidrug resistant cancer cells grown in culture. The cytotoxicity tests were performed on a variety of cancer cells including multidrug resistant, breast, ovarian, and pancreatic cancer cells. Soon after announcing these findings, the Company filed a provisional patent application for composition and utility subject matter pertaining to the structure and sequence of these mRNA molecules in the United States. These mRNA molecules bear the laboratory designation K1.1. During the early summer as the transmissibility of the Covid Omicron variants became more widespread we expanded our collaboration with the University of Arizona to accelerate the development of our novel PLpro inhibitors for our anti-Coronavirus treatment program. In October 2022 we announced what we consider to be our crown achievement of 2022, our acquisition of a Canadian generic pharmaceuticals company, Nora Pharma Inc., with sales of approximately $14 million. Sunshine Biopharma now has over 50 generic prescription drugs on the market in Canada with plans to grow further throughout North America and potentially other markets around the world. We have vigorously pushed forward with our oncology K1.1 mRNA development program by entering into a key collaboration arrangement with a leading lipid nano-particle (LNP) formulation company in North America. Our LNP collaboration partner is currently preparing two LNP formulations for our antineoplastic K1.1 mRNA (K1.1a and K1.1b). We had previously demonstrated that K1.1 mRNA is capable of destroying cancer cells in vitro, including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Parallel studies using normal human cells (HMEC) showed that K1.1 mRNA had little or no cytotoxic effects. Beginning in March, 2023, our partner generated K1.1-LNP formulations will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers as well as liver cancer. Should these mice studies prove successful, the Company can advance relatively rapidly to conducting human trials. The LNP formulated K1.1 mRNA can be readily adapted for delivery into patients using the recently gained knowledge from the mRNA vaccine technology. We believe we have a solid foundation to move the Company forward into 2023 and beyond. Our objectives going forward will be focused on: Achieving profitability on a priority basis; andContinuing to invest in our proprietary drug development program. On a personal note, I am excited about what we’ve accomplished in 2022 and look forward to what the future holds as we solidly navigate the Company through 2023 and beyond. As a scientist, my overarching life’s mission is to make the world a healthier place for all. On behalf of Sunshine Biopharma and our more than 40 employees, I would like to thank all of our shareholders and supporters. We appreciate the confidence you have placed in us and look forward to providing further updates as our progress continues. Wishing you an enjoyable Holiday Season and a healthy, happy, and prosperous New Year! Very Truly Yours, Dr. Steve Slilaty Chairman & CEOSunshine Biopharma Inc. Safe Harbor Forward-Looking Statements This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the “Company”) that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company’s drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company’s filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company’s most recent SEC filings. For Additional Information: Sunshine Biopharma Contact:Camille Sebaaly, CFODirect Line: 514-814-0464camille.sebaaly@sunshinebiopharma.com Sunshine Biopharma Media Contact:Christine PetragliaTraDigital IRDirect Line: 917-633-8980investors@sunshinebiopharma.com

MONTREAL, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today issued a letter to shareholders from Dr. Steve Slilaty, Chairman and CEO of the Company. Dear Fellow Sunshine Biopharma Shareholders, On behalf of Sunshine’s Board of Directors, our senior management team, and employees, we are delighted to have you as our shareholders and as valued stakeholders of our corporate family. I am writing this letter to provide you with some of the important developments that have occurred at Sunshine over this past year and some insights into what we see ahead. 2022 has been a transformative year for the Company despite some challenging headwinds with the economy and financial markets. On February 17, we completed an $8 million public offering and up-listed to NASDAQ. Shortly thereafter on March 14, we completed a private placement for total gross proceeds of another $8 million and on April 28 we closed a third offering for $19.5 million in gross proceeds. These offerings, together with additional funds of approximately $12 million received from the exercise of warrants included in the aforesaid offerings, enabled us to expand our proprietary drug development program and complete a key acquisition which set us on the path of becoming a fully-integrated biopharma company. In April, 2022, we announced our biopharma pipeline developments for mRNA molecules capable of destroying multidrug resistant cancer cells grown in culture. The cytotoxicity tests were performed on a variety of cancer cells including multidrug resistant, breast, ovarian, and pancreatic cancer cells. Soon after announcing these findings, the Company filed a provisional patent application for composition and utility subject matter pertaining to the structure and sequence of these mRNA molecules in the United States. These mRNA molecules bear the laboratory designation K1.1. During the early summer as the transmissibility of the Covid Omicron variants became more widespread we expanded our collaboration with the University of Arizona to accelerate the development of our novel PLpro inhibitors for our anti-Coronavirus treatment program. In October 2022 we announced what we consider to be our crown achievement of 2022, our acquisition of a Canadian generic pharmaceuticals company, Nora Pharma Inc., with sales of approximately $14 million. Sunshine Biopharma now has over 50 generic prescription drugs on the market in Canada with plans to grow further throughout North America and potentially other markets around the world. We have vigorously pushed forward with our oncology K1.1 mRNA development program by entering into a key collaboration arrangement with a leading lipid nano-particle (LNP) formulation company in North America. Our LNP collaboration partner is currently preparing two LNP formulations for our antineoplastic K1.1 mRNA (K1.1a and K1.1b). We had previously demonstrated that K1.1 mRNA is capable of destroying cancer cells in vitro, including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Parallel studies using normal human cells (HMEC) showed that K1.1 mRNA had little or no cytotoxic effects. Beginning in March, 2023, our partner generated K1.1-LNP formulations will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers as well as liver cancer. Should these mice studies prove successful, the Company can advance relatively rapidly to conducting human trials. The LNP formulated K1.1 mRNA can be readily adapted for delivery into patients using the recently gained knowledge from the mRNA vaccine technology. We believe we have a solid foundation to move the Company forward into 2023 and beyond. Our objectives going forward will be focused on: Achieving profitability on a priority basis; and Continuing to invest in our proprietary drug development program. On a personal note, I am excited about what we’ve accomplished in 2022 and look forward to what the future holds as we solidly navigate the Company through 2023 and beyond. As a scientist, my overarching life’s mission is to make the world a healthier place for all. On behalf of Sunshine Biopharma and our more than 40 employees, I would like to thank all of our shareholders and supporters. We appreciate the confidence you have placed in us and look forward to providing further updates as our progress continues. Wishing you an enjoyable Holiday Season and a healthy, happy, and prosperous New Year! Very Truly Yours, Dr. Steve Slilaty Chairman & CEO Sunshine Biopharma Inc. Safe Harbor Forward-Looking Statements This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the “Company”) that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company’s drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company’s filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company’s most recent SEC filings. For Additional Information: Sunshine Biopharma Contact: Camille Sebaaly, CFO Direct Line: 514-814-0464 camille.sebaaly@sunshinebiopharma.com Sunshine Biopharma Media Contact: Christine Petraglia TraDigital IR Direct Line: 917-633-8980 investors@sunshinebiopharma.com

DUBLIN, Dec. 19, 2022 /PRNewswire/ -- The "Global Biosimilars Partnering Terms and Agreements 2010 to 2022" report has been added to ResearchAndMarkets.com's offering. The Global Biosimilars Partnering Terms and Agreements 2010 to 2022 report provides an understanding and access to 190 biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains links to online copies of actual biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of biosimilars dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biosimilars dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading biosimilars deals since 2010. Deals are listed by headline value, signed by big pharma, most active biosimilars dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in biosimilars dealmaking with a brief summary followed by a comprehensive listing of biosimilars deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of biosimilars partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of biosimilars partnering deals signed and announced since Jan 2010. The chapter is organized by specific biosimilars technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by biosimilars partnering company A-Z, deal type definitions and biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Global Biosimilars Partnering Terms and Agreements 2010 to 2022 includes: Trends in biosimilars dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to over 190 biosimilars deal records and contract documents where available The leading biosimilar deals by value since 2010 Most active biosimilars dealmakers since 2010 The leading biosimilars partnering resources In Global Biosimilars Partnering Terms and Agreements 2010 to 2022, the available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy and technology target Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in biosimilars dealmaking 2.1. Introduction 2.2. Biosimilars partnering over the years 2.3. Most active biosimilars dealmakers 2.4. Biosimilars partnering by deal type 2.5. Biosimilars partnering by therapy area 2.6. Deal terms for biosimilars partnering 2.6.1 Biosimilars partnering headline values 2.6.2 Biosimilars deal upfront payments 2.6.3 Biosimilars deal milestone payments 2.6.4 Biosimilars royalty rates Chapter 3 - Leading biosimilars deals 3.1. Introduction 3.2. Top biosimilars deals by value Chapter 4 - Most active biosimilars dealmakers 4.1. Introduction 4.2. Most active biosimilars dealmakers 4.3. Most active biosimilars partnering company profiles Chapter 5 - Biosimilars contracts dealmaking directory 5.1. Introduction 5.2. Biosimilars contracts dealmaking directory Chapter 6 - Biosimilars dealmaking by technology type Appendices Appendix 1 - Biosimilars deals by company A-Z Appendix 2 - Biosimilars deals by stage of development Appendix 3 - Biosimilars deals by deal type Appendix 4 - Biosimilars deals by therapy area Appendix 5 - Appendix 6 - Recent report titles from Companies Mentioned 3SBio 180 Life Sciences Abbvie Abreos Biosciences Abzena Accord Healthcare Aceno Biotherapeutics AdAlta AET Biotech Aetos Biologics AffaMed Therapeutics Agila Specialties AIT Bioscience Algorithme Pharma Holdings Alteogen Altiora Alvogen Alvotech Amedica Amgen Amneal Pharmaceuticals Arecor Avid Bioservices Axantia Back-A-Line Bacterin International Baxalta Baxter International BeiGene Bio-Manguinhos/Fiocruz Bio-Thera Solutions Biocnd Biocon Bioeq IP Bio Farma Biogen Biooutsource BiosanaPharma BioSavita BioSciencesCorp Bioton BioXpress Boehringer Ingelheim Bolt Biotherapeutics Boston Oncology Bruker C-Bridge Capital Catalent CEA-Leti Celares Celerion Cellectis Celltrion Changchun High & New Technology Industries Chemo Sa Lugano Chungnam National University Cipla CJ Corp Clinigen Cobra Biologics Coherus Biosciences Compass Biotechnologies Concord Biosciences Cook Pharmica CR Pharma Daiichi Sankyo Diabeloop DM Corporation Dong-A ST Dr. Reddy's Laboratories Dyadic International EirGenix EMD Millipore Enzene Biosciences Epirus Biopharmaceuticals Epivax European Commission Evercyte Evotec Ewopharma Formosa Pharmaceuticals Formycon Fujifilm Fujifilm Kyowa Kirin Biologics Fuji Pharma GC Pharma Gedeon Richter GE Healthcare Genentech Genhelix Biopharmaceutical Genor Biopharma GenScript ProBio Gerresheimer Hadasit Medical Research Services and Development Hanwha Chemical Helvetic Biopharma Henlius Biotech Hikma Pharmaceuticals Hoffmann La Roche Horizon 2020 Hospira Innovent Biologics Intas Pharmaceuticals inVentiv Health Ipca Laboratories Ipsen Jacobson Pharma JAMP Pharma Group JHL Biotech Kamada Karolinska Institute Kemwell BioPharma Kymos Pharma Services Kyowa Hakko Kirin Laboratorios Liomont LABORATORIOS SAVAL Ligacept Livzon Mabpharm Lupin M+W Group Mab-Venture Biopharma Mabion mAbXience Medicago Medicure Medipolis Meiji Seika Merck and Co Merck BioVentures Merck KGaA Merck Serono MGC Diagnostics Ministry of Health (Brazil) Mithra Pharmaceuticals Mitsubishi Chemical Mochida Pharmaceutical Momenta Pharmaceuticals Mundipharma Mylan Laboratories Mylan Pharmaceuticals Nan Fung Group NanoLock Natco Pharmaceuticals National Cancer Institute National Comprehensive Cancer Network (NCCN) NCPC GeneTech Neoletix Biotechnology NeuClone Nora Pharma Novo Nordisk Ocumension Therapeutics Oncobiologics ORF Genetics Orox Pharmaceuticals Orygen Biotecnologia Pall Corporation Pangen Biotech Parexel PBS Biotech Perfinity Biosciences Pfenex Pfizer Pharmapark PharmaPraxis PlantForm PlantPraxis Biotecnologia Polpharma Portal Instruments PPD PRA Health Sciences Premier Inc Premier Research Prestige BioPharma ProBioGen PT Etana Biotechnologies Qilu Pharmaceutical Quanta BioDesign QuiaPEG Pharmaceuticals For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets